Idiopathic Pulmonary Fibrosis – Unmet Need – Detailed, Expanded Analysis
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. Individuals experience dyspnea and lung complications, which eventually cause respiratory failure. Boehringer Ingelheim’s Ofev and Roche / Genentech’s Esbriet are welcome options in the treatment armamentarium for IPF. Therapies that can further delay or reverse the disease’s progression, preserve lung function, and prolong survival are sorely needed. The diverse IPF pipeline comprises novel classes including prostacyclin vasodilators, CTGF inhibitors, ROCK 2 inhibitors, PDE4B inhibitors, Galectin-3 inhibitors, and agents targeting the LPA-1 receptor. In this report, we assess the clinical and commercial opportunities remaining in the IPF space through a comprehensive analysis of surveyed pulmonologists’ treatment drivers and goals and their perception of the performance of key current therapies against these goals.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for IPF?
- Which drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies such as Ofev and Esbriet perform on key treatment drivers and goals for IPF?
- What are the key opportunities for drug development in IPF? Where do surveyed pulmonologists perceive the largest gaps in the treatment of IPF?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European pulmonologists for a hypothetical new IPF drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 61 U.S. and 31 European pulmonologists fielded in March 2023
Key companies: Roche, Boehringer Ingelheim, FibroGen
Key drugs: Esbriet, Ofev, prednisone
Table of contents
- Idiopathic Pulmonary Fibrosis - Unmet Need - Detailed, Expanded Analysis
- Unmet need - IPF - TPP simulator - June 2023
- Executive summary
- Introduction
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed pulmonologists' prescribing decisions in IPF
- Importance of efficacy attributes to prescribing decisions in IPF: United States
- Importance of efficacy attributes to prescribing decisions in IPF: Europe
- Importance of safety and tolerability attributes to prescribing decisions in IPF: United States
- Importance of safety and tolerability attributes to prescribing decisions in IPF: Europe
- Importance of convenience of administration attributes to prescribing decisions in IPF: United States
- Importance of convenience of administration attributes to prescribing decisions in IPF: Europe
- Importance of nonclinical factors to prescribing decisions in IPF: United States
- Importance of nonclinical factors to prescribing decisions in IPF: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in IPF: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in IPF: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for IPF: United States
- Overall performance of key therapies for IPF: Europe
- Mean overall performance of key therapies for IPF: United States and Europe
- Relative performance of key therapies for IPF across select efficacy attributes: United States
- Relative performance of key therapies for IPF across select efficacy attributes: Europe
- Relative performance of key therapies for IPF across select safety and tolerability attributes: United States
- Relative performance of key therapies for IPF across select safety and tolerability attributes: Europe
- Relative performance of key therapies for IPF across select convenience of administration attributes: United States
- Relative performance of key therapies for IPF across select convenience of administration attributes: Europe
- Relative performance of key therapies for IPF across select nonclinical attributes: United States
- Relative performance of key therapies for IPF across select nonclinical attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in IPF
- Surveyed pulmonologistsu2019 satisfaction with the performance of key therapies for IPF on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed pulmonologistsu2019 satisfaction with the performance of key therapies for IPF on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed pulmonologistsu2019 ascribed level of unmet need across key efficacy attributes in IPF: United States
- Surveyed pulmonologistsu2019 ascribed level of unmet need across key efficacy attributes in IPF: Europe
- Surveyed pulmonologistsu2019 ascribed level of unmet need across key safety and tolerability attributes in IPF: United States
- Surveyed pulmonologists' ascribed level of unmet need across key safety and tolerability attributes in IPF: Europe
- Surveyed pulmonologists' ascribed level of unmet need across key convenience of administration attributes in IPF: United States
- Surveyed pulmonologists' ascribed level of unmet need across key convenience of administration attributes in IPF: Europe
- Surveyed pulmonologists' ascribed level of unmet need across key nonclinical factors in IPF: United States
- Surveyed pulmonologists' ascribed level of unmet need across key nonclinical factors in IPF: Europe
- Key findings: unmet need in IPF and related indications
- Surveyed pulmonologists' ascribed level of unmet need in IPF and related indications: United States
- Surveyed pulmonologists' ascribed level of unmet need in IPF and related indications: Europe
- Opportunity analysis
- Areas of opportunity in the IPF market and emerging therapy insights
- Opportunity: therapies demonstrating better preservation of lung function and prolongation of survival compared with current therapies
- Opportunity: therapies that can reduce daily symptoms and improve quality of life
- Opportunity: therapies that are more effective in preventing acute exacerbations
- Opportunity: additional effective therapies that have good safety and tolerability profiles
- Areas of opportunity in the IPF market and emerging therapy insights
- Target product profiles
- Appendix
Shreaa, M.B.A., is an associate healthcare and data analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. She conducts secondary and primary market research on U.S. and European biopharmaceutical markets. She holds an M.B.A. in pharmaceutical management from Jamia Hamdard in New Delhi.